Literature DB >> 6470756

Acivicin: a new glutamine antagonist in clinical trials.

P J O'Dwyer, M T Alonso, B Leyland-Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6470756     DOI: 10.1200/JCO.1984.2.9.1064

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

1.  A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study.

Authors:  S Baruchel; M Bernstein; V M Whitehead; S Devine; B Bell; R Dubowy; H Grier; C Kretschmar; A M Langevin; T Vietti
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

2.  Insulin and acivicin improve host nutrition and prevent tumor growth during total parenteral nutrition.

Authors:  W T Chance; L Cao; J E Fischer
Journal:  Ann Surg       Date:  1988-10       Impact factor: 12.969

Review 3.  Targeting Metabolism for Cancer Therapy.

Authors:  Alba Luengo; Dan Y Gui; Matthew G Vander Heiden
Journal:  Cell Chem Biol       Date:  2017-09-21       Impact factor: 8.116

4.  Accelerated methylmercury elimination in gamma-glutamyl transpeptidase-deficient mice.

Authors:  N Ballatori; W Wang; M W Lieberman
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

Review 5.  New agents in the treatment of primary brain tumors.

Authors:  S A Taylor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Phase I clinical trial of continuous infusion cyclopentenyl cytosine.

Authors:  P M Politi; F Xie; W Dahut; H Ford; J A Kelley; A Bastian; A Setser; C J Allegra; A P Chen; J M Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier.

Authors:  Y Takada; N H Greig; D T Vistica; S I Rapoport; Q R Smith
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.

Authors:  P J Elson; L K Kvols; S E Vogl; D J Glover; R G Hahn; D L Trump; P P Carbone; J D Earle; T E Davis
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

9.  Phase I-II trial of acivicin in adult acute leukemia.

Authors:  B L Powell; J B Craig; R L Capizzi; F Richards
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

10.  Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1.

Authors:  Ethan G Geier; Avner Schlessinger; Hao Fan; Jonathan E Gable; John J Irwin; Andrej Sali; Kathleen M Giacomini
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.